Jun 12, 2017 | By Tess

CollPlant, an Israel-based company specializing in regenerative medicine, has reportedly filed a patent in the United States for a 3D bioprinting ink which could be used to print tissues and organs. The bioink is based on CollPlant’s established rhCollagen technology, a proprietary plant-based product used for tissue repair applications.

With its recent patent application, CollPlant is signalling its intention to become a key player in the 3D bioprinting field, as it hopes to work with other bioprinting companies to supply printable bioinks.

According to the U.S. patent application, CollPlant’s new bioink is based on recombinant human collagen (rhCollagen), which the company says is a suitable “building block” for bioprinting and is identical to the naturally produced type I collagen. The new bioink could be used to print 3D scaffold structures embedded with human cells and growth factors for the production of tissues and even organs.

CollPlant’s bioink can also be formulated to include various other proteins or polymers, and is compatible with a range of different bioprinting processes, making it suitable for use by different bioprinting companies.

"We are promoting commercial collaborations with leading international companies in the field of 3D bioprinting of tissue and organ, with the aim of taking part in providing a solution to the significant need for life-saving organs,” explained Yehiel Tal, CEO of CollPlant.

“The new patent establishes CollPlant's technology status in 3D biological printing, creates barriers to entry for competitors and increases the trust of potential partners. CollPlant's technology is highly regarded by major international players, and our objective is to enter into our first significant collaboration this year.”

CollPlant first came onto our radar last year, as the company announced it was awarded a grant of $1.4 million for the purpose of investigating 3D bioprinting inks for organ development. The research grant was provided by Israel’s Ministry of Economy, which evidently understands the significance and potentials of bioprinting technologies.

More recently, CollPlant launched an entire division geared towards bioprinting research and development. The division was established specifically for the development of bioinks. Now, with the recent patent application, it seems CollPlant is taking significant steps towards bringing its 3D bioprinting materials to market.

In addition to bioprinting, CollPlant is also focused on developing solutions for the orthobiologics and advanced wound care markets. As always, we are excited to see more developments in the field of bioprinting, which is arguably one of the most important segments of the 3D printing industry.

 

 

Posted in 3D Printing Materials

 

 

Maybe you also like:


   






Leave a comment:

Your Name:

 


Subscribe us to

3ders.org Feeds 3ders.org twitter 3ders.org facebook   

About 3Ders.org

3Ders.org provides the latest news about 3D printing technology and 3D printers. We are now six years old and have around 1.5 million unique visitors per month.

News Archive